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Fragility fractures, those fractures which result from low level
trauma, have a large and growing socio-economic cost in
countries with aging populations. For example, in the UK, over
70 000 hip fractures occur annually, and the total cost of associated
care is over £2 billion. The sufferers of these fractures have 10%
mortality in the 30days after the event and up to 30% mortality
within a year.[1]
The bones of those considered to be at risk of a first fragility
fracture are often assessed with X-ray radiation, with a bone’s
density, or areal density, being predictive of its likelihood to
fracture. The predictive power of X-ray-measured density to
measure a fracture is conceptually ‘similar to the assessment
of the risk of stroke by blood pressure readings. Blood
pressure values are continuously distributed in the population,
as is BMD (Bone Mineral Density, areal density of the bone). In
the same way that a patient above a cut-off for blood pressure
is diagnosed as hypertensive, the diagnosis of osteoporosis is
based on a value for BMD below a cut-off threshold. As is the
case for blood pressure, there is no threshold of BMD that
discriminates absolutely between those who will or will not have
a clinical event [i.e. a fracture in the case of bones].’[2] The World
Health Organisation has set the BMD threshold for the diagnosis
of osteoporosis as 2.5 standard deviations below the average for
control subjects who are at their peak BMD.[3] Thus, being
diagnosed with osteoporosis does not guarantee that a fractureJ. Raman Spectrosc. 2015, 46, 610–618 © 2015 The Awill occur, and conversely having normal bone density is no
guarantee that a fracture will not occur.[2]
In short, bone-density-based techniques are vital for identifying
populations that are at higher risk of fracture but do not have high
sensitivity when it comes to identifying individuals who will go on
to have a fragility fracture (a meta-analysis of 11 studies involving
tens of thousands of participants has shown that bone-density-
based techniques can predict ~35% of hip fractures in populations
with osteopenia or osteoporosis).[4] Considering the prevalence and
cost of fragility fractures there is a great need for more effective
diagnostic tools.uthors. Journal of Raman Spectroscopy Published by John Wiley & Sons, Ltd.
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Spatially Offset Raman Spectroscopy (SORS) as a new clinical/
diagnostic tool for assessment of bone transcutaneously in vivo.
SORS utilises non-ionising infra-red light and, unlike X-ray-based
techniques, can retrieve information from both the mineral and
protein phases of the bone.[5,6] It has recently been demonstrated that
SORS can be used tomeasure pathological ratios ofmineral to organic
content in bone in vivo[7] and, because the ratio of mineral to organic
can account for a large percentage of bone’s mechanical
properties,[8–10] the technique may allow better discrimination be-
tween those who will or will not, go on to have a fragility fracture.
Bone composition, osteoporosis and fragility fracture
In his 1991 review Riggs wrote that osteoporosis is an abso-
lute decrease in the amount of bone, and that the bone that
is present is normal chemically and histologically.[11] In the
years following this review, studies appeared that were in
agreement with this view: ashing was used to show that cor-
tical and cancellous bone from fractured femoral necks had
similar mineral, organic and water content as controls, [12,13]
and quantitative backscattered electron imaging (qBSEi) was
used to show that there was no significant difference in the
bone mineralization density distribution (BMDD) between
cortical bone from the iliac crest of postmenopausal osteopo-
rotic women and controls.[14] Thermo-gravimetric analysis also
showed that bone from fractured femoral heads was as stable
as that from control bone.[13] X-ray diffraction of bone from
fractured femoral heads showed: (1) the mineral unit cell
dimensions and crystallite sizes to be the same as in control
bone, (2) the mean carbonate content to be almost the same
as in control bone (7.5 and 7.6%) and (3) the position of
the carbonate inclusions to be the same as in control bone
(i.e. they substituted for hydroxyl groups and phosphate groups
in the same way).[13]
The story did not stay simple; however, in 1993 Bailey et al.
used biochemical analysis to reveal that collagen from (OP)
fractured bone had different levels of post-translational modifi-
cations to that from control bone.[15] Specifically, the stabilising
cross-links and the hydroxylation of the collagen were increased
in fractured bone.[15] The qBSEi picture also became more
complicated; in addition to the identical BMDD finding
described above, the iliac crest study reported that the bone
from the OP group had a decreased calcium content.[14]
Another study of bone from fractured femoral necks and con-
trols showed the level of mineralisation to be lower in the
(OP) fractured bone,[16] and a third study reported that bone
from (OP) fractured femurs was under mineralised compared
to control bone.[17] The 2004 study was challenging the, by
now ‘traditional view’, that osteoporotic fractures were the re-
sult of a reduction in bone mass, remodelling effects and alter-
ations in the micro-architecture.[16]
Vibrational spectroscopy, osteoporosis and fragility fracture
The question of whether osteoporosis and fragility fractures are
associated with altered bone-tissue composition has also been
addressed with infrared and Raman spectroscopy of excised
bone.[5,18,19] Fourier transform infrared (FTIR) spectroscopy has
been used to show that the mineral in the bone tissue
from osteoporotic patients was more crystalline and the bone
has a lower mineral-to-collagen ratio than bone from control
patients.[20,21] FTIR imaging has been used to show thatJ. Raman Spectrosc. 2015, 46, 610–618 © 2015 The Authors. Journa
Published by John Wspectroscopic features related to collagen maturity, higher crystal-
linity and higher mineral-to-collagen ratio are associated with
higher risk of fragility fractures.[22]
A 2006 Raman spectroscopy study by the Morris group, which
looked at compositional differences in women with and without
osteoporotic fracture, suggested that the bone was indeed
chemically altered.[23] The data showed that the carbonate-to-
phosphate spectral band ratio was ~20% larger in bone from the
iliac crests of women who had suffered fragility fractures (the
standard deviations of these figures were overlapped and p=0.05).
It was also reported that the mineral-to-collagen ratio of bone from
the head of a fragility-fractured femur was ~30% greater than that
from a control femur (p=0.04 and 0.11 for carbonate/amide I ratio
and the phosphate ν1/amide I ratio, respectively).
[23]Present study
In the present study we use Raman spectroscopy and multivariate
analysis to measure compositional markers in excised fragility-
fractured bone and then explore the hypothesis that similar
Raman signals can bemeasured transcutaneously in vivo using SORS.
The first aim was to use Raman spectroscopy to identify
spectroscopic/chemical differences in bone excised from two
cohorts (one cohort who had suffered from hip fractures and
one cohort of donors who had not). We used the unsupervised
multivariate analysis technique, Principal Component Analysis
(PCA) rather than univariate measures (e.g. the intensity ratio
of different Raman bands) because it has been shown that
the statistical power of univariate measures can be lessened
by many experimental factors. For example, it has been
reported that changes in the relative alignment of the laser
polarisation and the orientation of the mineralised collagen
fibrils can cause somemineral to collagen ratios to change but leave
others unaffected,[24] that freezing the samples can cause some
Raman bands to change intensity more than others[25] and that
some mineral to collagen ratios can have more variance than
others.[26] Band ratios can also be affected by the presence of
fats/lipids which have Raman bands that overlap with collagen
Raman bands (a sample which is covered in marrow can appear to
have more intense collagen bands, i.e. be less mineralised).
The second aim of the study was to apply SORS and multivariate
analysis to look for the excised-bone Raman markers transcuta-
neously in vivo (the first SORS study to compare data from healthy
and diseased human cohorts). The in vivo study is not structured as
a clinical trial but as a clinical investigation which points the way
towards the development of SORS as a clinical tool for predicting
fragility fractures. After presenting the results we identify methodo-
logical developments which could improve the statistical signifi-
cance of our experiments and eventually lead to more sensitive
prediction of fragility fractures.Method/Materials
Excised bone samples and in vivo measurements
Excised bone samples
Ten femoral heads/necks were collected from elderly patients who
had undergone surgery after sustaining low-trauma intra-capsular
fragility fracture to the neck of femur (Watford General Hospital,
West Hertfordshire Hospitals NHS Trust, England). Each
patient gave written consent for the material to be retained anl of Raman Spectroscopy
iley & Sons, Ltd.
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12analysed. The femoral heads were retrieved en bloc during surgery
using a surgical helical drill. After retrieval the samples were stored
briefly in a fridge (4 °C) before being transported to the laboratory.
The control specimens were from ten cadaveric femora (from
six individuals) that were obtained from the Vesalius Clinical
Training Centre, University of Bristol, England. Five left femora
and five right femora were collected (fractures associated with
metastatic cancer were excluded from the study). The head/neck
of each femur was removed using an AEW Thurne 350 band saw
(AEW Delford Systems, Norwich, England) with a cutting speed of
27m/s.
The cortical density of the OP samples (as measured with pQCT)
was 810mgcm1 (std. dev. 37mgcm1) and the cortical density of
the control samples was 910mgcm1 (std. dev. 48mgcm1); the
age and gender of both the OP and the control donors are given
in Fig. 1.
Scalpels were used to the remove the soft tissue from
every sample (fractured and control); a 10-mm slice was cut
through the middle of each specimen in the coronal plane,
using the band saw described above. The coronal slices were then
washed and rinsed with deionised water to remove all visible
blood and lipid. All samples were stored in a freezer (80 °C) when
not in use.In vivo measurements
Ten patients, being treated for osteoporosis at the Royal
National Orthopaedic Hospital in London, were recruited into
the study. The patients all had T-scores of <2.5 in either their
hip or their spine and were clinically diagnosed as osteoporotic.
On average the cohort had a (left) hip T-score of2.4 (std. dev. 0.6)
and a spine T-score of 2.4 (std. dev. 1.2). They were all receiving
bisphosphonate treatment for osteoporosis (zolendronate (n= 9),
alendronate (n= 1)), and all but three participants had had at least
one fragility fracture. Six controls, patients with no history of bone
disease or fragility fractures, were also recruited into the study at
the Royal National Orthopaedic Hospital in London. The ages and
genders of the sixteen in vivo subjects are shown in Fig. 1. All
participants were non-smokers.Figure 1. The age and gender of the excised-bone donors and the in vivo
patients. In each group the ‘controls’ are on the left and the ‘diseased’ are on
the right. The males are plotted as crosses and the females as circles (two
circles overlap at 75 years in the ‘diseased’ -in vivo group).
wileyonlinelibrary.com/journal/jrs © 2015 The Authors. Journa
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Excised bone samples
The Raman spectra were collected with a Renishaw ‘inVia’ Raman
microscope (Renishaw plc., Gloucestershire, England). The instru-
ment utilised a 300-mW, 830-nm laser and a Leica microscope with
an Olympus 50×/0.5 long working distance objective lens; the
optical setup resulted in losses of ~50% (i.e. laser power at the
sample was ~150mW). The laser power at the sample was ~10mW.
Each spectrum was collected for 90 s (3×30 s accumulations), and
a minimum of fifteen spectra were taken from the cortical bone of
each femoral neck (the superior and inferior cortices were probed).
The samples were allowed to thaw at room temperature for a
minimum of 60min before any spectra were collected. The spectra
were not collected from areas of bone that were within 2mm of the
fracture line, visible damage or cracks.[23]
In vivo measurements
The SORS instrument used to collect the in vivo Raman spectra was
custom built by Cobalt Light Systems Ltd (Oxfordshire, England). It
also utilised an 830-nm near infrared laser. For the zero offset
spectra, the laser illumination point (1-mm spot size) and the
collection point were co-incident, and the laser power was
30mW. For the SORS spectra the light was delivered as a ring
(~1mm thick) with variable radius (spatial offset) of up to 10mm,
the collection point was the centre of the ring.[27] For the SORS
measurements the laser power in the ring was capped at 30mW
per 3.5-mm diameter aperture (as per BS EN 60825-1:2007, the
safety standard relevant to laser light on skin). Therefore the laser
power when the beam was a spot (and less than 3.5mm across)
was 30mW, but when it was a 1-mm-thick ring with radius 8mm
it was approximately 150mW, i.e. the power automatically
increased with increasing illumination area but did not exceed
the safety limit.
The collected Raman light was transmitted through a fibre-optic
bundle into a spectrograph with a charge-coupled device (CCD—
Andor iDus 420 BR-DD) detector at its output. To aid overall
collection efficiency, the (low OH content CeramOptec, NA=0.28)
fibre bundle used a round configuration of 33 200-μm-diameter
fibres to collect the filtered Raman signal; the spectrograph end
of the fibre bundle was configured as a linear array to fill both the
spectrograph input slit and the available vertical extent of the
CCD optimally. The detector had a spectral resolution of ~8 cm1,
and it automatically removed any spurious signals caused by
cosmic-ray events (by comparing successive spectra and looking
for outliers).
Each patient had Raman spectra collected from the phalangeal
bones in the fingers and flat anterio-medial face of the proximal
tibiae. The SORS offset at the fingers was 5mm, and the SORS offset
at the tibia was 8mm. The accumulation time for each spectrum
was 60×1 s.Data processing and analysis
Data processing
The broad fluorescence background was removed from each
spectrum (both excised and in vivo) using a polynomial fitting
routine[28] (script written in-house on MATLAB—The Mathworks
Inc., version 2013a). The excised spectra were then normalised to
the intensity of the phosphate ν1 band (Microsoft Office Excel).l of Raman Spectroscopy
iley & Sons, Ltd.
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First, the excised-bone spectra were trimmed in order to focus on
the spectral region that contained the collagen bands and a
reference mineral band (the carbonate band). They were then
normalised to the intensity of the carbonate mineral band and
analysed using PCA with scripts that were written for MATLAB.[29,30]
Principal component analysis (PCA) decomposes the data matrix
into orthogonal factors and ranks them in order of variance; when
the excised spectra were decomposed, it was clear that the first
(main) eigenvector could be used as a measure of collagen content
(eigenvectors still represent a linear combination of the true spectra
and thus are not usually interpreted as pure component
information but the appearance of the eigenvector (Fig. 3A) makes
it clear that it is dominated by collagen). The loading, or weight on
this main eigenvector, was used in the rest of the analysis/figures.
Decomposition of the in vivo spectra
The in vivo Raman spectra, which contained contributions from
skin, lipids and bone, needed to be spectrally decomposed before
they could be analysed.[6] First, each spectrum was normalised to
the intensity of the lipid band at 1299 cm1, and spectra with weak
mineral bands were eliminated (the phosphate ν1 intensity lost its
shape and disappeared into other Raman-band envelopes at
~0.45, all spectra with ν1 intensity below 0.45 were discounted);
this resulted in a data set of at least five spectra from each
individual (i.e. at least 5min accumulation time from each
individual). In our previous work[6] we have shown that a bone
spectrum can be successfully removed from in vivo SORS data
using parallel factor analysis, but in the present study, in which
we had to make do with smaller data sets, we found that the best
spectral decomposition was achieved with Band Target Entropy
Minimisation (BTEM).[31–33]
The BTEM decomposition was performed using a software
routine that was written in-house; the data from each individual
patient was combined into a file = ‘X, Y1, Y2, Y3…Y~10’ (because a
BTEM analysis was used to obtain a single ‘bone’ spectrum from
each person individually the algorithm saw/removed no varianceFigure 2. The average bone spectrum from each of the 20 excised femoral nec
(10 fractured and 10 controls, n= 10 and n= 6, respectively).
J. Raman Spectrosc. 2015, 46, 610–618 © 2015 The Authors. Journa
Published by John Wrelated to health-disease, age, gender, etc.). The BTEM algorithm
(which also had a non-negativity term) targeted the ν1 phosphate
band (959–963 cm1) and operated on the first five eigenvectors
(‘the first few vectors are associated with real chemically important
signals in the system and the remainder are associated primarily
with the random instrumental and experimental noise’[31]).
Principal component analysis—in vivo spectra
The BTEM spectra that were obtained from each patient (shown in
Fig. 5) represented estimates of pure bone spectra that could be
compared with each other. Before they were compared they were
processed further; first, they were spectrally trimmed in order to
focus on the spectral region that contained the collagen bands
and a reference mineral band (the carbonate band). The amide I
band (at ~1660 cm1) was also removed as the signal at this posi-
tion was subject to considerably higher tissue absorption than
Raman signals at lower wavenumbers (SORS photons have long
migration paths; this magnifies differences between wavelength-
dependent absorption coefficients).[6] The trimmed spectra were
normalised to the intensity of the carbonate mineral band.
The data were then analysed using PCA with scripts that were
written for MATLAB.[29,30] When the BTEM spectra were
decomposed, it was clear that the first (main) eigenvector could
be used as a measure of collagen content (as before, it is necessary
to be aware that eigenvectors represent a linear combination of the
true spectra and thus are not usually interpreted as pure
component information but once again the appearance of the
eigenvector (Fig. 6A) makes it clear that it is dominated by
collagen). The loading, or weight on this main eigenvector, was
used in the rest of the analysis/figures.
Results
Excised bone samples
The average spectrum from each of the 20 excised femoral necks
(ten fractured and ten controls, n=10 and n=6, respectively) is
shown in Fig. 2; the spectra are normalised to the ν1 phosphateks; they have been normalised to the dominant (ν1 phosphate) mineral band
l of Raman Spectroscopy
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14band at 960 cm1 making it apparent that the collagen bands are
less intense (in relative terms) in the fractured specimens than in
the control specimens.
The difference between the two sets of specimens (averages and
overlaps) is shown in the multivariate analysis in Fig. 3; Fig. 3A
shows the collagen eigenvector, the spectral feature which
represented most of the variance in the data, and Fig. 3B shows
the weighting that eigenvector has for each spectrum. There is a
data point for every spectrum collected. The data points in Fig. 3B
emphasise the point that the fractured femoral necks have a higher
ratio of mineral-to-collagen than the bone from the control femoral
necks (p< 0.0001) and that there is a large overlap between the
two sets of values.
Fig. S1 shows the same data as Fig. 3B but underneath is plotted
a single data point for each individual (an average of all the spectra
from each person). The collapse of the intra-individual variance
upon averaging illustrates how the heterogeneity of bone on the
millimetre-scale canmake itmore difficult to diagnose the presence
of the bone disease using point spectra.[34] When every spectrumFigure 3. A. The reduced spectral region (from 987 cm1 to 1800 cm1) and th
average spectrum is shown in the background. B. The ‘collagen score’ for each
Figure 4. The average spectrum from the excised control bones and the avera
mineral band); they have been reconstructed using the information from F
reconstruction are shown for illustration.
wileyonlinelibrary.com/journal/jrs © 2015 The Authors. Journa
Published by John Wfrom each specimen is averaged the bone from the fractured
femoral necks still has a significantly higher ratio of mineral to
collagen than the control femoral necks (p< 0.02), but there is still
considerable overlap between the two cohorts.
The average Raman spectrum for the control and fractured bone
specimens can be reconstructed from the data from Fig. 3, and the
difference in mineralisation can be visualised (Fig. 4). The
reconstructed spectra reveal that the average fractured femoral
neck bone is 5–10% more mineralised (depending on which
mineral/collagen bands are used in the calculation, it is 5.5% if
the whole collagen region 988–1800 cm1 is used). Univariate
analyses of the Raman spectra, which illustrate how using different
Raman bands can affect the result, are also shown in the
supplementary data (Fig. S2 and Table S1).
In vivo measurements
The BTEM-decomposed spectra retrieved from each of the 16
subjects scanned (10 osteoporotic and 6 controls) are shown in Fig. 5.e principal ‘collagen’ eigenvector associated with the excised specimens. The
excised-bone spectrum. The two classes are heavily overlapped.
ge spectrum from the excised fractured bone (normalised to the carbonate/
ig. 3. The other bands (below 1000 cm1) which were not used for the
l of Raman Spectroscopy
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Figure 5. The BTEM spectrum retrieved transcutaneously from each of the
16 subjects scanned (10 osteoporotic and 6 controls).
Prediction of fragility fractures with Raman spectroscopyFigure 6A shows the dominant eigenvector, and Fig. 6B
shows weighting its score for each BTEM spectrum (i.e. one
spectrum for each individual). The OP BTEM-spectra have, onFigure 6. A. The reduced spectral region (from 987 cm1 to 1540 cm1) and th
spectrum is shown in the background. B. The ‘collagen score’ for each spectrum
Figure 7. In vivomeasurements: the average control and average osteoporosis
other bands (below 1000 cm1) which were not used for the reconstruction are
J. Raman Spectrosc. 2015, 46, 610–618 © 2015 The Authors. Journa
Published by John Waverage, greater mineral-to-collagen ratios than the control
BTEM-spectra (in agreement with the excised bone data), but
the difference between the two populations is not statistically
significant (p = 0.56).
When average spectra are reconstructed for the control and
fractured bone specimens using the information in Fig. 6,
the difference in mineral-to-collagen ratio can be visualised
(Fig. 7). It is also possible to use this information to calculate
that spectra from a minimum of 116 people (i.e. 58 osteopo-
rotic and 58 controls) would be required to test whether the
two populations are different (to strength of p= 0.05).Discussion
Raman spectroscopy and multivariate analysis have been used to
show that bone fragments from the fractured femoral necks are
more mineralised (by 5–10%, p< 0.02) than the bone from the
non-fractured controls, but there is a large overlap between the
mineralisation distributions. One can calculate how well one could
predict a fragility fracture of the hip if one had access to thee principal ‘collagen’ eigenvector for the in vivomeasurements. The average
. The two classes are heavily overlapped.
spectra that have been reconstructed using the information from Fig. 6. The
shown for illustration.
l of Raman Spectroscopy
iley & Sons, Ltd.
wileyonlinelibrary.com/journal/jrs
6
15
K. Buckley et al.
6
16averaged spectra by taking the mean and standard deviations of
the two groups and assuming that mineral-to-collagen ratios in
groups have normal distributions. If we set the specificity at 90%
(which is higher than the specificity of bone-density-based
techniques when predicting hip fractures in populations with
osteopenia or osteoporosis)[4] then the averaged-excised Raman
data would predict more than 75% of hip fractures, a sensitivity
more than twice that of bone-density-based techniques.[4]
The combination of SORS, BTEM and PCA has been used to
measure bone composition of cohorts of healthy and osteoporosis
individuals in vivo. The comparative differences we detected
between the osteoporosis cohort and healthy cohorts were in the
same direction (increased mineral-to-collagen ratio) as that
between the excised-fractured and excised-controls. The distance
between the average spectrum from each group also exhibited a
similar magnitude change (an increase of 10.0± 2.5% for
comparable spectral regions, see Fig. 4 and Fig. 7) and the two
cohorts were heavily overlapped. These results, however, did not
reach statistical significance.
The observed increase in mineral-to-collagen ratio is in agree-
ment with a previous study.[23] The findings cannot be explained
by reference to increase in bone remodelling (in individuals
with fragility-structures/osteoporosis) because remodelling would
cause spectral changes in the opposite direction, i.e. increased
remodelling would be expected to increase the proportion of
new/under-mineralised osteoid and thus decrease the mineral-to-
collagen ratio.Limitations of the work and scope for improvement
The current work suffered from a number of limitations related to
recruiting appropriate cohorts and securing comparative excised
bone samples.
Patient age matching
Figure 1 illustrates the age differences between the experimental
groups and the control groups in this study; the donors of the
excised-fracture bones were on average 11years older than the
cadaveric donors of the excised control-bone (85 vs 74), and
the in vivo-osteoporosis patients were on average 9 years older
than the in vivo-control patients (70 vs 61).
There is evidence in the literature that bone mineral content
varies with age[35–39]and that it decreases in non-fractured
individuals in the last decades of life.[40,41] We investigated the
relationship between age and the collagen-eigenvector loading in
our cohorts and found no association (Fig. 8).Figure 8. The relationship between the age (in years) versus the weight on th
wileyonlinelibrary.com/journal/jrs © 2015 The Authors. Journa
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Figure 1 shows that the donors of the excised-fracture bones (all
women) were not gender matched with the cadaveric donors of
the excised control-bone (mostly men) and the in vivo-osteoporotic
patients (all women) were not gender-matched with the in vivo-
control patients (mostly men). There is evidence in the literature
that men have a higher bone mineral content than women[37,38]
but our ‘more male’ groups both have lower mineral-to-collagen
ratio than our ‘more female’ groups which suggests the gender
matching does not affect the findings (there is also biomechanical
evidence that at thematerial level bone frommen is similar to bone
from women[42]). We did not have enough control data to test
statistically whether there was a relationship between gender and
the collagen-eigenvector, but what data we did have is plotted in
supplementary Fig. S3.
Bisphosphonates
Bisphosphonates are a class of drug with a high affinity for the
crystal surface of bone mineral and an inhibitory effect on bone
resorption cells. Bisphosphonates’ main action is to increase bone
mass.[43]
The excised-fractured bone samples used in this study came
from people whose first presentation to clinicians was with their
fragility fracture; thus, none of them had been diagnosed with
osteoporosis and/or put on bisphosphonates. The excised-control
bone came to us from cadaveric donors, and we only had access
to partial medical records; the bones were not visibly affected by
osteoporosis or, fragility fractures but we cannot be 100% sure
that none of them had been prescribed bisphosphonates during
their life.
Because of the difficulty of finding osteoporotic patients who are
not receiving treatment and who want to take part in a scientific
investigation, all of the members of our osteoporosis-in vivo cohort
were taking bisphosphonates.
There is a growing body of literature on the effect bisphos-
phonates can have on bone composition. Studies on model
systems have reported that bisphosphonates can affect how the
crystals grow in bone mineral (thus affecting the size of the crystals,
the degree of carbonate inclusion, etc.) and can cause a reduction
in mineral-to-collagen ratio (in beagle dogs and ovariectomised
monkeys).[43]
Vibrational spectroscopy studies of pelvic bone biopsies from
humans have also shown a relationship between bisphosphonates
and bone composition. In one study, which looked at bone
at 0 years (baseline), 3 years and 5 years, it was shown thate PC1 loading for the excised data (left) and the in vivo data (right).
l of Raman Spectroscopy
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17mineral-to-collagen ratio and collagen cross-link ratio of untreated
women increased with time whereas they stayed flat for women
treated with risedronate (a bisphosphonate).[44] In another study
of human pelvic bone biopsies, the drugs made no difference in
the crystallinity or collagen maturity but decreased the carbonate-
to-phosphate ratio by ~15% and increased the phosphate-to-
amide I ratio (a measure of the mineral to collagen ratio) by
20–25%.[45] The chemical change found in our in vivo study of
similar cohort is in the same direction, but the difference we ob-
served is smaller (and statistically underpowered).
In another more recent study of the effects of bisphosphonate,
bone biopsies were obtained from over 100 women (four cohorts:
alendronate (a bisphosphonate) for 3–5 years, alendronate for
>5 years, risedronate (a different bisphosphonate) for 3–5 years
and risedronate for >5 years). It was shown that in strictly
age-controlled bone (i.e. the age of the bone was controlled for
rather than the age of the subject) there was no difference in
mineral-to-collagen ratio between the four cohorts.[46]
It is likely that there is no complication related to
bisphosphonates in our excised-bone data but that there is in our
in vivo data; it will take improvements in our SORS methodology
and larger cohorts of patients before we can say any more about
them.
Anatomical-site matching
As discussed in the introduction above there is much evidence in
the literature that there is a relationship between propensity to
suffer fragility fractures and bone composition (where bone
composition encompasses mineral-to-collagen ratio, mineral
composition, collagen crosslinking, etc.); it is known that bone
tissue composition varies in different anatomical sites,[47,48] but it is
interesting to consider whether compositional changes associated
with fracture are localised or skeleton-wide.
An individual is at an increased risk of fragility fracture if they
have already suffered a fragility fracture in the past, for example a
women who has had a vertebral fracture has ~4 times greater risk
of having subsequent vertebral fractures than a women who has
not had a prior fracture. More interestingly, an individual who has
had one fragility fracture is about twice as likely to have a second
fragility fracture at any other anatomical site as someone who has
never had a fragility fracture; for example someone who has
fractured their wrist is twice as likely to subsequently break their
hip as someonewho has never fractured awrist.[49] Of course, many
risk factors for fragility fractures are clearly related to the whole
person (e.g. cigarette smoking or propensity to fall) and so the
two fractures could be considered independent events happening
in the same body.[2,50]
In a previous paper, we explored the regional adaptation of bone
composition in the ends of long bones and showed that it had a
lowermineral to collagen ratio (i.e. is less stiff) than bone found near
the mid-shaft.[48] We discussed how any disruption to this
mineralisation pattern could lead to unsuitably stiff bone being
found at the proximal and distal ends of the cortex. The increase
of 5–10% in the mineral to collagen ratio reported in the present
study is enough to affect bone’s material properties. For example,
an increase of ~10% would increase the Young’s modulus by
~10%.[10] This change in material properties could also change
the mechanical properties of the whole femoral neck indirectly.
Computer models, in which bone deformations below a certain
threshold cause resorption and bone deformations above another
threshold induced bone formation, have shown that an increaseJ. Raman Spectrosc. 2015, 46, 610–618 © 2015 The Authors. Journa
Published by John Win stiffness of the magnitude shown here could cause the loss of
approximately 20% of the bone volume and also lead to large
increases in the anisotropy of the bone architecture.[51] Thus the
patients who donated the excised-fractured bone may have had
a localised over-mineralisation which affected their ability to resist
fracture directly (material property changes) and indirectly (led to
increased bone resorption and anisotropy).
The questions about localised changes in bone composition
are related to this study because the exercised-fracture (and
exercised-control) bone probedwith conventional Raman spectros-
copy was from the cortex of the femoral neck and these data were
compared and contrasted with in vivo SORS data, which were
collected from fingers and tibiae.
Future methodological improvements
At all stages of the in vivo study there were aspects that we will be
able to improve as we move towards the prediction of fragility
fractures transcutaneously.
• The patient recruitment: more efforts will be made to age and
gendermatch the patients (this will dispel lingering questions
about, for instance, differences in skin thickness)
• Data collection, the laser power that was used in the study
was conservative and there is scope for increasing it by an or-
der of magnitude.[52] The throughput of the Raman collection
system can also be dramatically increased by opening the
spectrometer slit and using a higher dispersion grating (this
is at the expense of a narrowed spectral range)[52]
• Spectral decomposition, the BTEM decomposition routine
which strips away the soft tissue spectra and leaves the bone
spectrum is perhaps the limiting factor in the present paper.
Higher fidelity bone spectra may be achieved by accounting
for tissue absorption in future analysis
• The multivariate analysis of the final (decomposed) spectra
may be improved by using more sophisticated techniques,
for example by combining PCA with linear discriminant
analysis
Added together these measures provide scope for major im-
provements andmay enable to deliver a method that complements
or substitutes the traditional bone-density-based techniques.
Conclusion
On average the bone in fractured femoral necks has a higher
mineral-to-collagen ratio than the bone from intact controls, but
there is a large overlap in the mineralisation distributions of
the two groups. In our in vivo measurements, the first in vivo
SORS measurements of bone in healthy and diseased human
cohorts reported, we show similar but as of yet statistically
underpowered differences.
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